{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:54:14Z","timestamp":1769604854620,"version":"3.49.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.hoc.2016.07.009","type":"journal-article","created":{"date-parts":[[2016,11,24]],"date-time":"2016-11-24T01:05:03Z","timestamp":1479949503000},"page":"1333-1343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["Update on Burkitt Lymphoma"],"prefix":"10.1016","volume":"30","author":[{"given":"Kieron","family":"Dunleavy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard F.","family":"Little","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wyndham H.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"197","key":"10.1016\/j.hoc.2016.07.009_bib1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/bjs.18004619704","article-title":"A\u00a0sarcoma involving the jaws in African children","volume":"46","author":"Burkitt","year":"1958","journal-title":"Br J Surg"},{"key":"10.1016\/j.hoc.2016.07.009_bib2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1182\/asheducation-2007.1.277","article-title":"Burkitt lymphoma: revisiting the pathogenesis of a virus-associated malignancy","author":"Kelly","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.hoc.2016.07.009_bib3","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1182\/asheducation-2005.1.260","article-title":"Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas","author":"Heslop","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9","key":"10.1016\/j.hoc.2016.07.009_bib4","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1128\/jvi.68.9.6069-6073.1994","article-title":"Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV","volume":"68","author":"Shimizu","year":"1994","journal-title":"J\u00a0Virol"},{"issue":"11","key":"10.1016\/j.hoc.2016.07.009_bib5","doi-asserted-by":"crossref","first-page":"9150","DOI":"10.1128\/JVI.72.11.9150-9156.1998","article-title":"Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata","volume":"72","author":"Komano","year":"1998","journal-title":"J\u00a0Virol"},{"issue":"35","key":"10.1016\/j.hoc.2016.07.009_bib6","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.1038\/sj.onc.1210324","article-title":"Epstein-Barr virus promotes genomic instability in Burkitt's lymphoma","volume":"26","author":"Kamranvar","year":"2007","journal-title":"Oncogene"},{"issue":"40","key":"10.1016\/j.hoc.2016.07.009_bib7","doi-asserted-by":"crossref","first-page":"14935","DOI":"10.1073\/pnas.0509988103","article-title":"Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells","volume":"103","author":"Kelly","year":"2006","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"4","key":"10.1016\/j.hoc.2016.07.009_bib8","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.cell.2015.07.019","article-title":"Plasmodium infection promotes genomic instability and AID-dependent B cell lymphoma","volume":"162","author":"Robbiani","year":"2015","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.hoc.2016.07.009_bib9","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nrmicro1089","article-title":"Endemic Burkitt's lymphoma: a polymicrobial disease?","volume":"3","author":"Rochford","year":"2005","journal-title":"Nat Rev Microbiol"},{"issue":"6","key":"10.1016\/j.hoc.2016.07.009_bib10","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.semcancer.2009.10.002","article-title":"Endemic Burkitt's lymphoma as a polymicrobial disease: new insights on the interaction between Plasmodium falciparum and Epstein-Barr virus","volume":"19","author":"Chene","year":"2009","journal-title":"Semin Cancer Biol"},{"issue":"24","key":"10.1016\/j.hoc.2016.07.009_bib11","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.1073\/pnas.79.24.7824","article-title":"Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells","volume":"79","author":"Dalla-Favera","year":"1982","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"12","key":"10.1016\/j.hoc.2016.07.009_bib12","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/leu.2011.156","article-title":"The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma","volume":"25","author":"Lenze","year":"2011","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.hoc.2016.07.009_bib13","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1182\/blood-2010-08-301556","article-title":"Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes","volume":"117","author":"Piccaluga","year":"2011","journal-title":"Blood"},{"issue":"7418","key":"10.1016\/j.hoc.2016.07.009_bib14","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature11378","article-title":"Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics","volume":"490","author":"Schmitz","year":"2012","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.hoc.2016.07.009_bib15","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/ng.2468","article-title":"The genetic landscape of mutations in Burkitt lymphoma","volume":"44","author":"Love","year":"2012","journal-title":"Nat Genet"},{"issue":"12","key":"10.1016\/j.hoc.2016.07.009_bib16","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/ng.2469","article-title":"Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing","volume":"44","author":"Richter","year":"2012","journal-title":"Nat Genet"},{"issue":"23","key":"10.1016\/j.hoc.2016.07.009_bib17","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa055759","article-title":"Molecular diagnosis of Burkitt's lymphoma","volume":"354","author":"Dave","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.hoc.2016.07.009_bib18","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa055351","article-title":"A\u00a0biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling","volume":"354","author":"Hummel","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2016.07.009_bib19","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1365-2141.2011.08947.x","article-title":"RD-CODOX-M\/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma","volume":"156","author":"Corazzelli","year":"2012","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.hoc.2016.07.009_bib20","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood-2008-03-145128","article-title":"A\u00a0prospective clinicopathologic study of dose-modified CODOX-M\/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC\/NCRI LY10 trial)","volume":"112","author":"Mead","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2016.07.009_bib21","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/j.1365-2141.2008.07144.x","article-title":"Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB\/LMB 96 international study","volume":"141","author":"Gerrard","year":"2008","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.hoc.2016.07.009_bib22","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V97.11.3370","article-title":"The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia","volume":"97","author":"Patte","year":"2001","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2016.07.009_bib23","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/annonc\/mdi403","article-title":"Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol","volume":"16","author":"Divine","year":"2005","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2016.07.009_bib24","first-page":"3294","article-title":"Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90","volume":"94","author":"Reiter","year":"1999","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2016.07.009_bib25","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1200\/JCO.1996.14.3.925","article-title":"Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen","volume":"14","author":"Magrath","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2016.07.009_bib26","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1200\/JCO.1999.17.8.2461","article-title":"Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia","volume":"17","author":"Thomas","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2016.07.009_bib27","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.hoc.2016.07.009_bib28","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood.V120.21.685.685","article-title":"Addition of rituximab improves outcome of HIV negative patients with randomized lymphoma treated with the LMBA protocol: results of the randomized intergroup (GRAALL-LYSA) LMBA02 protocol [abstract]","volume":"120","author":"Ribrag","year":"2012","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.hoc.2016.07.009_bib29","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1182\/blood-2014-03-563627","article-title":"Improved outcome of adult Burkitt lymphoma\/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial","volume":"124","author":"Hoelzer","year":"2014","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.hoc.2016.07.009_bib30","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1200\/JCO.2007.13.1391","article-title":"Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers","volume":"26","author":"Wilson","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"10.1016\/j.hoc.2016.07.009_bib31","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa1308392","article-title":"Low-intensity therapy in adults with Burkitt's lymphoma","volume":"369","author":"Dunleavy","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.hoc.2016.07.009_bib32","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1182\/blood.V126.23.342.342","article-title":"Risk-adapted therapy in adults with burkitt lymphoma: preliminary report of a multicenter prospective phase II study of DA-EPOCH-R [abstract]","volume":"126","author":"Dunleavy","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2016.07.009_bib33","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.1996.14.9.2465","article-title":"Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma\u2014outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation","volume":"14","author":"Sweetenham","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2016.07.009_bib34","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1182\/blood-2002-11-3589","article-title":"Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology","volume":"101","author":"Little","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2016.07.009_bib35","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood-2015-01-623900","article-title":"AMC 048: modified CODOX-M\/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma","volume":"126","author":"Noy","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.009_bib36","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1038\/onc.2013.242","article-title":"Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors","volume":"33","author":"Tolani","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.hoc.2016.07.009_bib37","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1158\/1078-0432.CCR-13-3346","article-title":"Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma","volume":"21","author":"Trabucco","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"26","key":"10.1016\/j.hoc.2016.07.009_bib38","doi-asserted-by":"crossref","first-page":"E2721","DOI":"10.1073\/pnas.1406722111","article-title":"BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma","volume":"111","author":"Bhadury","year":"2014","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2016.07.009_bib39","doi-asserted-by":"crossref","first-page":"e1152","DOI":"10.1038\/cddis.2014.112","article-title":"Inhibition of human mitochondrial peptide deformylase causes apoptosis in c-myc-overexpressing hematopoietic cancers","volume":"5","author":"Sheth","year":"2014","journal-title":"Cell Death Dis"},{"issue":"7","key":"10.1016\/j.hoc.2016.07.009_bib40","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1074\/jbc.M113.525949","article-title":"SIRT4 protein suppresses tumor formation in genetic models of Myc-induced B cell lymphoma","volume":"289","author":"Jeong","year":"2014","journal-title":"J\u00a0Biol Chem"},{"issue":"6","key":"10.1016\/j.hoc.2016.07.009_bib41","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T\u00a0cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858816300971?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858816300971?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:03:49Z","timestamp":1760184229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858816300971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0889858816300971"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2016.07.009","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on Burkitt Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2016.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}